News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Grateful to ASCO for prioritizing our well-being with SafeHaven™ – Toni Choueiri
Photo from Toni Choueiri/Twitter
Jul 21, 2023, 18:53

Grateful to ASCO for prioritizing our well-being with SafeHaven™ – Toni Choueiri

Grateful to ASCO for prioritizing our well-being with SafeHaven™, a clinician well-being program! Thank you for this incredible initiative to support us in both our professional and personal lives.

Your well-being matters! Enroll now: asco.safehavenhealth.org/enroll/

Source: Toni Choueiri/Twitter

ASCO cancer clinician OncoDaily Oncology SafeHaven Toni Choueiri
Insight
Jul 27, 2024, 13:30
Piotr Wysocki: Impact of genomic risk on response to extended adjuvant endocrine therapy
Insight
Jul 27, 2024, 13:23
Myeloma Paper of the Day, July 27th, suggested by Robert Orlowski
Blog
Jul 27, 2024, 13:18
Oncoinfluencers to Follow on Social Media: Dr. Rami Manochakian
Blog
Jul 27, 2024, 13:06
St. Baldrick's Venture Philosophy: Funding Osteosarcoma Research
Blog
Jul 27, 2024, 13:03
Yakup Ergün: Can we truly label a study with Grade 5 toxicity as 'acceptable' or 'manageable'?
Blog
Jul 27, 2024, 12:54
Cincinnati Cancer Advisors has received a grant from the Bell Charitable Foundation!
Insight
Jul 27, 2024, 12:46
Jacob Thompson: Excited to announce the publication of my first peer-reviewed article
Insight
Jul 27, 2024, 12:41
ACCO has secured more than $100 million in state funding for childhood cancer research
Insight
Jul 27, 2024, 12:31
Bringing Death Back Into Life, Grand Rounds with Aditi Sethi - IOWG
Blog
Jul 27, 2024, 12:06
Julie McCrossin: 3 things we can do to improve the physical and emotional recovery of Head and Neck Cancer patients
Blog
Jul 27, 2024, 12:01
Ask the Expert with Amer Zeidan
Blog
Jul 27, 2024, 11:35
Daniel Shapiro: Pleased to present our thoughts on the current adjuvant trials for RCC